World Health Organization Issues Warning Over Severe Lack of Obesity Medications
Under a tenth of individuals eligible to benefit from weight-loss injections including Wegovy have access to them, warns the WHO as it issues its first guidance on the therapies.
With over a billion people worldwide now obese, it is urging increased and just availability to this class of drugs.
Per forecasts, more than two billion will be living with obesity by 2030 unless action is taken.
"Our latest guidance affirms that excess weight is a long-term condition that can be managed with comprehensive and lifelong treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant hurdles to universal availability to the jabs that can assist patients in reducing significant weight, notes the organization.
Skinny Jab Shortage
Despite the present most optimistic case, the supply of these medications might only reach around 100 million people – less than 10% of the global need, as stated by the health organization.
The guideline encourages countries and companies to expand availability, via approaches such as licensing agreements.
Exclusive production rights on the active ingredient – the core ingredient of a leading brand – is due to expire in multiple nations in 2026.
How Obesity Drugs Function
The injections replicate a body's own hormone to slow digestion, suppress the appetite and increase satiety so users reduce food intake.
People typically begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Studies suggests users may regain a significant portion within a year of stopping the medication, when their normal food cravings resume.
Being overweight or obese increases your likelihood for experiencing medical conditions, including diabetes, heart disease, brain attack, and specific malignancies.
Excess weight concerns people in every country and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
